48 results about "Simian immunodeficiency virus" patented technology

The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.

The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and / or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.

The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The invention relates to the production and use of retroviral vectors for cell specific gene transfer, specially to a production method of retroviral vectors containing capsid particles of murine leukemia virus (MLV) and envelope proteins of human immunodeficiency vises (HIV) or simian immunodeficiency viruses (SIV). Said vectors can be used for gene transfer in selected cell types, specially in CD4-positive mammal cells.

The present invention is directed to vaccine compositions that can be used to protect cats against feline immunodeficiency virus. More particularly, the present invention relates to polynucleotide molecules that can be used as vaccine components against feline immunodeficiency virus.

Highly efficient gene transfer into primate-derived embryonic stem (ES) cells has successfully been achieved by using a simian immunodeficiency virus vector (SIV) pseudotyped with VSV-G protein, which is a surface glycoprotein of vesicular stomatitis virus (VSV) The present invention provides simian immunodeficiency virus vectors for gene transfer to primate ES cells. The method for gene transfer to primate ES cells using the vectors of the present invention is useful in, for example, research into embryology and disease, clinical applications, and experimental models for primates. The method is also useful in assaying and screening for genes and reagents able to enhance the specific differentiation of tissues or cells, and which are useful in preparing desired cells or tissues differentiated from ES cells.

The present invention relates to a class of proteins, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified modified venom composition.

The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The

The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified and neurotropically active modified venom composition containing alpha-neurotoxins that target a nicotinic acetylcholine receptor.

This invention relates to a Hybrid immunodeficiency virus strain and application, Human immunodeficiency virus (HIV-1) B' hypotype, R5 tropism, hybrid human / simian immunodeficiency virus strain (SHIV-B'WHU) and 3'end chimeric plasmids used to construct this virus and the use of this virus in stablishing simian / AIDS animal model. At genome framework of simian immunodeficiency virus SIVmac239, gene segment of B'HIV-1 replaces SIVmac239 gene to constitute SHIV-B'WHU. The constituted Hybrid virus SHIV-B'WHU takes along adventitial gene of B'hypotype HIV-1, possessing R5 tropism, it can infect PBMC of human and Macaca rhesus out-of-body and be effectively reproduced, ensuring that SHIV-B'WHU infect Macaca rhesus to construct simian / AIDS animal model. It will be used for researching HIV such as: process of infection in body, etiological agent characteristic, etiopathogenesis,immune reaction and so on, and screening and evaluating AIDS vaccine, anti-HIV drug and microbicide.

This invention relates to compositions for the treatment of acquired immunodeficiency diseases, especially human immunodeficiency virus (HIV), and its simian and feline counterparts (simian immunodeficiency virus (SIV), and feline immunodeficiency virus (FIV)), and to methods for their use.

The invention provides a cocktail vaccine that is anti-immune tolerance and anti-immunodeficiency virus and its application. Said cocktail vaccine at least comprises two or more elements and any viral antigen recombinant protein and medical shaping. Said element is recombinant DNA and / or recombinant virus; it is chosen from (A) neutralizing antibody, receptor antagonist, membrane fusion blocking agent, cell factor coding sequence, and / or DNA interference sequence; (B) immunoadjuvants coded sequence; (C) antigen gene, viral antigen and immunoadjuvants fusion gene, viral antigen epitope coded sequence, multi-epitope fusion gene and / or viral antigen epitope -MHC-I SCT gene; (D) two seven-peptide multiplexed sequence HR1 and HR2 of membrana capsularis virus fusion protein and / or coded sequence of its polymer HR212. The expression carrier of all antiviral elements comprises recombinant DNA carrier, vaccinia virus carrier and / or adenoviral carrier.

The present disclosure provides methods and compositions for reducing the reservoir of latent immunodeficiency virus in an individual, and for treating an immunodeficiency virus infection in an individual.

The invention discloses a method for extracting antiviral active substance from phellinus igniarius, which relates to a method for extracting active substance from traditional Chinese medicine. The method includes the following steps that: phellinus igniarius fruit bodies are dehydrated and ground under low temperature; ethyl acetate which is 2 to 10 times as large as the volume of the ground fruit bodies is added in the ground fruit bodies to carry out extraction, ultrasonic oscillation is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder A. 90 percent of ethanol which is 2 to 10 times as large as the volume of filter residue extracted by the ethyl acetate is added into the filter residue to carry out extraction, ultrasonic oscillation is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder B. Water with the temperature of 20 DEG C, which is 5 to 30 times as large as the volume of filter residue extracted by the ethanol is added in the filter residue, ultrasonic extraction is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder C. According to the weight percentage ratio of 10 percent to 80 percent : 10 percent to 80 percent : 10 percent to 80 percent, the powder A, the powder B and the powder C are uniformly mixed. The obtained active substance has a good effect in resisting simian immunodeficiency virus (SIV), herpes virus (HSV) and enterovirus (EV71).

The present invention belongs to the field of chemical synthetic medicine, and provides a kind of rare-earth heteropolyacid salt (blue) medicine for resisting AIDS. Said ivnention provides its general formula. Said medicine is low in toxic side effect, and has the strong action for inhibiting virus replication for HIV infected cell and SIV (acute simian immunodeficiency virus).

Highly efficient gene transfer into primate-derived embryonic stem (ES) cells has successfully been achieved by using a simian immunodeficiency virus vector (SIV) pseudotyped with VSV-G protein, which is a surface glycoprotein of vesicular stomatitis virus (VSV) The present invention provides simian immunodeficiency virus vectors for gene transfer to primate ES cells. The method for gene transfer to primate ES cells using the vectors of the present invention is useful in, for example, research into embryology and disease, clinical applications, and experimental models for primates. The method is also useful in assaying and screening for genes and reagents able to enhance the specific differentiation of tissues or cells, and which are useful in preparing desired cells or tissues differentiated from ES cells.

This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial vims (RSV), human parainfluenza virus (HPV), measles virus (MeV). and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The invention discloses an RT-LAMP (reverse transcription and loop-mediated isothermal amplification) detection primer group, an RT-LAMP detection kit and an RT-LAMP detection method for a simian immunodeficiency virus. The detection primer group comprises a pair of outer primers, a pair of loop primers and a pair of inner primers. The detection kit comprises the primer group, RT-LAMP reaction liquid, Bst DNA polymerase, reverse transcriptase as well as negative control and positive control. The detection method comprises the following steps: extracting to-be-detected virus RNA; conducting reverse transcription on the RNA under the action of revertase; then, amplifying a sample template by virtue of six specific primers and one Bst DNA polymerase having strand displacement activity at 63-65 DEG C; and judging whether a to-be-detected sample contains the simian immunodeficiency virus (SIV) RNA by observing whether a reaction tube solution becomes muddy or not with naked eyes or performing electrophoresis to analyze whether a ladder exists or not. The detection primer group, the detection kit and the detection method provided by the invention have the advantages of being highly specific, high in sensitivity, rapid and efficient, simple and convenient to operate, easy in result reading and the like, and are suitable for popularization and application in grassroots animal epidemic disease monitoring units and experimental monkey breeding enterprises in remote areas.

The invention discloses a preparation method of an SIV (simian immunodeficiency virus) vector. A culture dish is treated with collagen by a calcium phosphate coprecipitation transfection process; and in the transfection process, an Opti-MEM culture medium is used, and the DNA (deoxyribonucleic acid) concentration is increased. The invention has the advantages of ingenious concept and low production cost; and the prepared tolvaptan tablet has the advantages of high in-vitro dissolution, high drug bioavailability and favorable clinical curative effect.

This invention relates to a process for producing a Simian Immunodeficiency Virus (SIV) encoding a heterologous gene, which process comprises infecting a host cell with a first vector which is capable of producing SIV capsid and a second vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal sufficient to package the second vector in the SIV capsid and a heterologous gene capable of being expressed by the vector; and culturing the host cell.

The present invention provides a monoclonal antibody specific for an epitope which is unique to the surface protein component of an inactivated feline immunodeficiency virus (FIV) envelope glycoprotein. Said antibody is useful for the quantification of inactivated FIV or the determination of the potency of an inactivated FIV vaccine.

The invention discloses a recombinant plasmid. The recombinant plasmid contains a gp120 gene of the monkey immunodeficiency virus and at least one cell wall carrier protein gene of Mycobacterium tuberculosis. The invention also discloses recombinant mycobacterium smegmatis which can stably express the gp120 gene of the monkey immunodeficiency virus and at least one cell wall carrier protein gene of Mycobacterium tuberculosis. The invention also discloses an AIDS vaccine and a preparation method thereof. The AIDS vaccine contains the recombinant mycobacterium smegmatis, is easy to culture, grows fast and saves time, labor, material resources and financial resources. The vaccine comprising three strains of the recombinant mycobacterium smegmatis ZWY2 exhibiting the SIV gp120 antigen proteinon the surface can stably exhibit the SIV gp120 antigen protein on the surface of the mycobacterium smegmatis ZWY2 and has the immunological effect in C57 mice far superior to that of intracellular expression of the antigen protein gp120 and that of the already published AIDS vaccine exhibiting gp120 on the surface based on adenovirus vector construction.

The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.

The invention discloses a method for extracting antiviral active substance from phellinus igniarius, which relates to a method for extracting active substance from traditional Chinese medicine. The method includes the following steps that: phellinus igniarius fruit bodies are dehydrated and ground under low temperature; ethyl acetate which is 2 to 10 times as large as the volume of the ground fruit bodies is added in the ground fruit bodies to carry out extraction, ultrasonic oscillation is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder A. 90 percent of ethanol which is 2 to 10 times as large as the volume of filter residue extracted by the ethyl acetate is added into the filter residue to carry out extraction, ultrasonicoscillation is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder B. Water with the temperature of 20 DEG C, which is 5 to 30 times as large as the volume of filter residue extracted by the ethanol is added in the filter residue, ultrasonic extraction is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder C. According to the weight percentage ratio of 10 percent to 80 percent : 10 percent to 80 percent : 10 percent to 80 percent, the powder A, the powder B and the powder C are uniformly mixed. The obtained active substance has a good effect in resisting simian immunodeficiency virus (SIV), herpes virus (HSV) and enterovirus (EV71).

Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing. The gp300 is useful for detecting antibodies to HIV-2 antigens in human body fluids and for raising antibodies to gp300.

The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.